Understanding Tardive Dyskinesia & DRBA Induced Movement Disorders

People may be experiencing changes in the status of their mental health, and some individuals living with a mental health condition may experience tardive dyskinesia (TD). TD is an involuntary movement disorder associated with prolonged use of antipsychotics commonly prescribed to treat schizophrenia, bipolar disorder, and depression.

Neurocrine Biosciences, is committed to the safety, health, and well-being of our patients, customers, employees, and healthcare providers and are proud to share the attached resource(s) to help educate and inform your team about TD.

We are sharing some information summarizing select resources available through our population health management program. The Population Health Care Collaborative provides materials to help educate staff and/or residents about the impact of movement disorders on individuals with serious mental illness.

This webinar will cover what Tardive Dyskinesia is as well as how to assess for it. Key best practices will be discussed and what to do once TD symptoms have been identified. Join us for an informative session.

Learning Objectives

After participating in this educational program the participant will be able to:

• Identify at least two risk factors for development of Tardive Dyskinesia.

• Determine how often patients on antipsychotic medication should be screened for Tardive Dyskinesia.

• Describe the steps involved on performing an AIMS assessment.

Speaker:

Diane Darling, RPh, PharmD, BCGP

Associate Director, Managed Care Liaison